State-based chronic disease control: the Rocky Mountain tobacco-free challenge
Article Abstract:
The Surgeon General established the year 2000 as a target date for making the United States a "smoke-free society." To further that ambition, governors from Arizona, Colorado, Montana, New Mexico, North Dakota, South Dakota, Utah and Wyoming established the Rocky Mountain Tobacco-Free Challenge (RMTFC). Members of this group attempt to further the Surgeon General's call by competitively challenging each other to reach that goal. Each year, tobacco-use reduction programs are evaluated and the most effective programs are identified. Last year's leader was North Dakota, followed by New Mexico and Colorado. Two important elements of the program are the active participation of the eight governors, and the competitive approach which is used to strengthen activities designed to reduce the use of tobacco. Reduction of tobacco use by adolescents through public information programs is imperative. Stimulation of local involvement in the RMTFC is considered essential to tobacco control and to national progress toward the goal of a smoke-free society.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1989
User Contributions:
Comment about this article or add new information about this topic:
Chronic Myelogenous Leukemia
Article Abstract:
Chronic myelogenous leukemia (CML) is one of the first cancers for which targeted therapy has been evaluated. Targeted therapy means creating a drug that targets cancer cells while leaving normal cells untouched. In the case of CML, the cause of the cancer is a chromosome abnormality that produces an enzyme called tyrosine kinase. This enzyme can be inhibited by drugs.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
A 41-year-old woman with chronic myelogenous leukemia
Article Abstract:
The symptoms, diagnosis, treatment, and prognosis of chronic myelogenous leukemia are reviewed based on the case of a 41-year-old woman. Leukemia is a cancer that affects white blood cells. Treatments include hydroxyurea, interferon, busulfan, imatinib, and stem cell transplants.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Inhibition of telomerase limits the growth of human cancer cells. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
- Abstracts: Breast pain. Chronic pain: considering the role of medication. Joint replacement: Help for when pain changes your lifestyle
- Abstracts: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. Evaluating Patients With Arthritis of Recent Onset: Studies in Pathogenesis and Prognosis
- Abstracts: Delayed cerebellar disease and death after accidental exposure to dimethylmercury. The death of young king Edward VI
- Abstracts: Interferon for chronic viral hepatitis. Interferon plus ribavirin for chronic hepatitis C. Pegylated interferon (PEG-Intron) for chronic hepatitis C